Biotech entity

AlpE

Product

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention BV100, the most common co-covered peer. The tracked stories average 2 original sources each. AlpE appears in 1 tracked Biotech story from March 18, 2026.

Last mentioned: Mar 18, 2026

RSS updates
Share

Entity pulse

Recent coverage · AlpE

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about AlpE

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention BV100, the most common co-covered peer. The tracked stories average 2 original sources each. AlpE appears in 1 tracked Biotech story from March 18, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering AlpE. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. 2025 Earnings Release

    BioVersys officially reports 2025 financial results and corporate highlights.

  2. AlpE Phase 2b Milestone

    First patient dosed in the Phase 2b clinical trial of AlpE for pulmonary tuberculosis.

  3. Reporting Announcement

    Company announces date for full-year 2025 results and business update.

  4. Fiscal Year End

    BioVersys concludes its 2025 fiscal year with key pipeline advancements.

Stories mentioning AlpE 1

Pharma Neutral

BioVersys Advances AMR Pipeline with Phase 2b Milestone and 2025 Results

BioVersys AG reported its full-year 2025 financial results, highlighting the successful transition of its lead candidate AlpE into Phase 2b clinical trials for pulmonary tuberculosis. The company's progress underscores its leadership in the antimicrobial resistance (AMR) space as it moves toward late-stage clinical validation.

2 sources

AlpE is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.